Women's interest in chemoprevention for breast cancer

Lori A. Bastian, Isaac M. Lipkus, Maggie N. Kuchibhatla, Haoling Holly Weng, Susan Halabi, Paula D. Ryan, Celette Sugg Skinner, Barbara K. Rimer

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Chemoprevention is the use of pharmacologic or natural agents to inhibit the development of cancer. Tamoxifen citrate is the only approved chemopreventive agent for breast cancer. We sought to determine whether women are interested in taking a drug to prevent breast cancer and to assess the relationship between objective and subjective breast cancer risk and interest in chemoprevention. Methods: We conducted telephone interviews (November 3, 1997, to May 6, 1998) among a community sample of women aged 40 to 45 and 50 to 55 years enrolled in a randomized controlled trial to evaluate the efficacy of a tailored mammography decision aid. Objective breast cancer risk was measured using the 5-year Gail score. Subjective breast cancer risk was measured using perceptions of absolute risk, perceptions of comparative risk, and worry about getting breast cancer. At 12-month follow-up (November 2, 1998, to July 20, 1999), we measured interest in taking a drug to prevent breast cancer. Results: Among the 1273 women surveyed, 23% were interested in taking a drug to prevent breast cancer; 8% were potentially eligible for tamoxifen therapy (5-year Gail score ≥1.66%). Eligibility for chemoprevention, based on the 5-year Gail score, was not associated with interest in taking a drug to prevent breast cancer. Women who were worried about breast cancer were 3 times more likely to be interested in taking a drug to prevent breast cancer than those who were not worried. Conclusion: Women's interest in chemoprevention might arise more from worries about getting breast cancer than from their objective risk factors.

Original languageEnglish (US)
Pages (from-to)1639-1644
Number of pages6
JournalArchives of Internal Medicine
Volume161
Issue number13
StatePublished - 2001

Fingerprint

Chemoprevention
Breast Neoplasms
Pharmaceutical Preparations
Tamoxifen
Decision Support Techniques
Mammography
Randomized Controlled Trials
Interviews

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Bastian, L. A., Lipkus, I. M., Kuchibhatla, M. N., Weng, H. H., Halabi, S., Ryan, P. D., ... Rimer, B. K. (2001). Women's interest in chemoprevention for breast cancer. Archives of Internal Medicine, 161(13), 1639-1644.

Women's interest in chemoprevention for breast cancer. / Bastian, Lori A.; Lipkus, Isaac M.; Kuchibhatla, Maggie N.; Weng, Haoling Holly; Halabi, Susan; Ryan, Paula D.; Skinner, Celette Sugg; Rimer, Barbara K.

In: Archives of Internal Medicine, Vol. 161, No. 13, 2001, p. 1639-1644.

Research output: Contribution to journalArticle

Bastian, LA, Lipkus, IM, Kuchibhatla, MN, Weng, HH, Halabi, S, Ryan, PD, Skinner, CS & Rimer, BK 2001, 'Women's interest in chemoprevention for breast cancer', Archives of Internal Medicine, vol. 161, no. 13, pp. 1639-1644.
Bastian LA, Lipkus IM, Kuchibhatla MN, Weng HH, Halabi S, Ryan PD et al. Women's interest in chemoprevention for breast cancer. Archives of Internal Medicine. 2001;161(13):1639-1644.
Bastian, Lori A. ; Lipkus, Isaac M. ; Kuchibhatla, Maggie N. ; Weng, Haoling Holly ; Halabi, Susan ; Ryan, Paula D. ; Skinner, Celette Sugg ; Rimer, Barbara K. / Women's interest in chemoprevention for breast cancer. In: Archives of Internal Medicine. 2001 ; Vol. 161, No. 13. pp. 1639-1644.
@article{12b7dfc72ce34e7fb6a6145b821f9184,
title = "Women's interest in chemoprevention for breast cancer",
abstract = "Background: Chemoprevention is the use of pharmacologic or natural agents to inhibit the development of cancer. Tamoxifen citrate is the only approved chemopreventive agent for breast cancer. We sought to determine whether women are interested in taking a drug to prevent breast cancer and to assess the relationship between objective and subjective breast cancer risk and interest in chemoprevention. Methods: We conducted telephone interviews (November 3, 1997, to May 6, 1998) among a community sample of women aged 40 to 45 and 50 to 55 years enrolled in a randomized controlled trial to evaluate the efficacy of a tailored mammography decision aid. Objective breast cancer risk was measured using the 5-year Gail score. Subjective breast cancer risk was measured using perceptions of absolute risk, perceptions of comparative risk, and worry about getting breast cancer. At 12-month follow-up (November 2, 1998, to July 20, 1999), we measured interest in taking a drug to prevent breast cancer. Results: Among the 1273 women surveyed, 23{\%} were interested in taking a drug to prevent breast cancer; 8{\%} were potentially eligible for tamoxifen therapy (5-year Gail score ≥1.66{\%}). Eligibility for chemoprevention, based on the 5-year Gail score, was not associated with interest in taking a drug to prevent breast cancer. Women who were worried about breast cancer were 3 times more likely to be interested in taking a drug to prevent breast cancer than those who were not worried. Conclusion: Women's interest in chemoprevention might arise more from worries about getting breast cancer than from their objective risk factors.",
author = "Bastian, {Lori A.} and Lipkus, {Isaac M.} and Kuchibhatla, {Maggie N.} and Weng, {Haoling Holly} and Susan Halabi and Ryan, {Paula D.} and Skinner, {Celette Sugg} and Rimer, {Barbara K.}",
year = "2001",
language = "English (US)",
volume = "161",
pages = "1639--1644",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "13",

}

TY - JOUR

T1 - Women's interest in chemoprevention for breast cancer

AU - Bastian, Lori A.

AU - Lipkus, Isaac M.

AU - Kuchibhatla, Maggie N.

AU - Weng, Haoling Holly

AU - Halabi, Susan

AU - Ryan, Paula D.

AU - Skinner, Celette Sugg

AU - Rimer, Barbara K.

PY - 2001

Y1 - 2001

N2 - Background: Chemoprevention is the use of pharmacologic or natural agents to inhibit the development of cancer. Tamoxifen citrate is the only approved chemopreventive agent for breast cancer. We sought to determine whether women are interested in taking a drug to prevent breast cancer and to assess the relationship between objective and subjective breast cancer risk and interest in chemoprevention. Methods: We conducted telephone interviews (November 3, 1997, to May 6, 1998) among a community sample of women aged 40 to 45 and 50 to 55 years enrolled in a randomized controlled trial to evaluate the efficacy of a tailored mammography decision aid. Objective breast cancer risk was measured using the 5-year Gail score. Subjective breast cancer risk was measured using perceptions of absolute risk, perceptions of comparative risk, and worry about getting breast cancer. At 12-month follow-up (November 2, 1998, to July 20, 1999), we measured interest in taking a drug to prevent breast cancer. Results: Among the 1273 women surveyed, 23% were interested in taking a drug to prevent breast cancer; 8% were potentially eligible for tamoxifen therapy (5-year Gail score ≥1.66%). Eligibility for chemoprevention, based on the 5-year Gail score, was not associated with interest in taking a drug to prevent breast cancer. Women who were worried about breast cancer were 3 times more likely to be interested in taking a drug to prevent breast cancer than those who were not worried. Conclusion: Women's interest in chemoprevention might arise more from worries about getting breast cancer than from their objective risk factors.

AB - Background: Chemoprevention is the use of pharmacologic or natural agents to inhibit the development of cancer. Tamoxifen citrate is the only approved chemopreventive agent for breast cancer. We sought to determine whether women are interested in taking a drug to prevent breast cancer and to assess the relationship between objective and subjective breast cancer risk and interest in chemoprevention. Methods: We conducted telephone interviews (November 3, 1997, to May 6, 1998) among a community sample of women aged 40 to 45 and 50 to 55 years enrolled in a randomized controlled trial to evaluate the efficacy of a tailored mammography decision aid. Objective breast cancer risk was measured using the 5-year Gail score. Subjective breast cancer risk was measured using perceptions of absolute risk, perceptions of comparative risk, and worry about getting breast cancer. At 12-month follow-up (November 2, 1998, to July 20, 1999), we measured interest in taking a drug to prevent breast cancer. Results: Among the 1273 women surveyed, 23% were interested in taking a drug to prevent breast cancer; 8% were potentially eligible for tamoxifen therapy (5-year Gail score ≥1.66%). Eligibility for chemoprevention, based on the 5-year Gail score, was not associated with interest in taking a drug to prevent breast cancer. Women who were worried about breast cancer were 3 times more likely to be interested in taking a drug to prevent breast cancer than those who were not worried. Conclusion: Women's interest in chemoprevention might arise more from worries about getting breast cancer than from their objective risk factors.

UR - http://www.scopus.com/inward/record.url?scp=0034919157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034919157&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 1639

EP - 1644

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 13

ER -